论文部分内容阅读
倍他洛尔(betaxolol,商标名称 Kerlone)为特异性肾上腺素神经β_1-受体阻滞剂,新近在美国批准用于降低血压及减慢心率。倍他洛尔对β-受体的阻断作用比普萘洛尔(心得安)更强。对正常人因运动而心率加速者,其减慢心率的效应为普萘洛尔的4倍。它对受体没有局部激动作用,仅有微弱的膜稳定作用。对动物或人,它抑制异丙肾上腺素产生的正性频率作用,并降低血压,还抑制肾上腺素对狗产生的室性心律失常,但不能抑制洋地黄产生的异位心律。
Betaxolol, a brand name of Kerlone, is a specific adrenergic neuroleptic beta 1-receptor blocker recently approved in the United States for lowering blood pressure and slowing heart rate. Beta-lorazol has more potent β-receptor blockade than propranolol (propranolol). For normal people due to exercise and heart rate acceleration, the effect of slowing heart rate is 4 times that of propranolol. It has no local agonism of the receptor, only a weak membrane stabilizing effect. It inhibits the positive frequency of isoproterenol production in animals or humans and lowers blood pressure and also inhibits ventricular arrhythmias induced by adrenaline in dogs but does not inhibit ectopic heart rhythms produced by digitalis.